SSY Group Wins NMPA Approvals for Two New Bulk Drug Products

SSY Group ( (HK:2005) ) has issued an update.

SSY Group Limited has secured approvals from China’s National Medical Products Administration for Phloroglucinol Trimethyl Ether and Dobutamine Hydrochloride as bulk drugs for market-ready preparations, deepening its presence in injectables. The group previously obtained approval to produce phloroglucinol injection, reinforcing its capabilities in treating spasmodic pain and heart failure and signaling continued expansion of its specialty hospital treatment portfolio in China.

The newly approved Phloroglucinol Trimethyl Ether supports injections targeting acute spasmodic pain associated with digestive, biliary, urinary and gynecological conditions, potentially strengthening SSY’s competitive edge in pain management therapies. Dobutamine Hydrochloride will be used for injections aimed at heart failure due to reduced myocardial contractility, including post–open-heart surgery low-output syndrome, enhancing the group’s offerings in critical-care cardiovascular drugs and potentially widening its clinical adoption in Chinese hospitals.

The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a pharmaceutical company listed in Hong Kong that develops and produces drug formulations and bulk active pharmaceutical ingredients. The group focuses on injectable medicines for hospital and clinical use in China, aligning its product portfolio with treatments for cardiovascular, digestive, urinary and gynecological conditions.

YTD Price Performance: 4.95%

Average Trading Volume: 4,943,570

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.76B

Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.